{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:12:11Z","timestamp":1791727931316,"version":"4.3.4"},"reference-count":39,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors reduce weight and improve insulin sensitivity via different mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The efficacy of once-weekly exenatide (EQW) and dapagliflozin (DAPA) alone and coadministered (EQW\/DAPA), DAPA\/extended-release (ER) metformin (DAPA\/MET), and phentermine topiramate extended release (PHEN\/TPM) on metabolic parameters, body composition, and sex hormones were examined in obese women with PCOS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Nondiabetic women (n\u2005=\u2005119; aged 18-45 years) with a body mass index (BMI) greater than 30 and less than 45 and polycystic ovary syndrome (National Institutes of Health criteria) were randomly assigned in a single-blinded fashion to EQW (2 mg weekly); DAPA (10 mg daily), EQW\/DAPA (2 mg weekly\/10 mg daily), DAPA (10 mg)\/MET (2000 mg XR daily), or PHEN (7.5 mg)\/TPM (46 mg ER daily) treatment for 24 weeks. Study visits at baseline and 24 weeks included weight, blood pressure (BP), waist (WC) measures, and body composition evaluated by dual-energy x-ray absorptiometry (DXA). Oral glucose tolerance tests were conducted to assess glycemia and mean blood glucose (MBG), and compute insulin sensitivity (SI) and secretion (IS) measures. Sex steroids, free androgen index (FAI), and lipid profiles were measured in the fasting sample.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>EQW\/DAPA and PHEN\/TPM resulted in the most loss of weight and total body fat by DXA, and WC. Despite equivalent reductions in BMI and WC with PHEN\/TPM, only EQW\/DAPA and EQW resulted in significant improvements in MBG, SI, and IS. Reductions in fasting glucose, testosterone, FAI, and BP were seen with all drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dual therapy with EQW\/DAPA was superior to either alone, DAPA\/MET and PHEN\/TPM in terms of clinical and metabolic benefits in this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgab408","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T10:59:14Z","timestamp":1623063554000},"page":"3019-3033","source":"Crossref","is-referenced-by-count":83,"title":["Exenatide, Dapagliflozin, or Phentermine\/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome"],"prefix":"10.1210","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3577-4009","authenticated-orcid":false,"given":"Karen E","family":"Elkind-Hirsch","sequence":"first","affiliation":[{"name":"Woman\u2019s Hospital Research Center, Woman\u2019s Hospital, Baton Rouge, Louisiana, USA"},{"name":"Woman\u2019s Weight Loss and Metabolic Clinic, Woman\u2019s Hospital, Baton Rouge, Louisiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Chappell","sequence":"additional","affiliation":[{"name":"Fertility Answers, Woman\u2019s Hospital, Baton Rouge, Louisiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ericka","family":"Seidemann","sequence":"additional","affiliation":[{"name":"Woman\u2019s Hospital Research Center, Woman\u2019s Hospital, Baton Rouge, Louisiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Storment","sequence":"additional","affiliation":[{"name":"Fertility Answers, Woman\u2019s Hospital, Baton Rouge, Louisiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drake","family":"Bellanger","sequence":"additional","affiliation":[{"name":"Woman\u2019s Weight Loss and Metabolic Clinic, Woman\u2019s Hospital, Baton Rouge, Louisiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,6,7]]},"reference":[{"key":"2021110612090058200_CIT0001","doi-asserted-by":"crossref","first-page":"16057","DOI":"10.1038\/nrdp.2016.57","article-title":"Polycystic ovary syndrome","volume":"2","author":"Azziz","year":"2016","journal-title":"Nat Rev Dis Primers."},{"issue":"1","key":"2021110612090058200_CIT0002","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/REP-19-0197","article-title":"Mechanisms of intergenerational transmission of polycystic ovary syndrome","volume":"159","author":"Dumesic","year":"2020","journal-title":"Reproduction."},{"issue":"3","key":"2021110612090058200_CIT0003","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40291-020-00463-w","article-title":"Deciphering the DNA methylome of polycystic ovary syndrome","volume":"24","author":"Tan","year":"2020","journal-title":"Mol Diagn Ther."},{"issue":"6","key":"2021110612090058200_CIT0004","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1210\/er.2011-1034","article-title":"Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications","volume":"33","author":"Diamanti-Kandarakis","year":"2012","journal-title":"Endocr Rev."},{"issue":"6","key":"2021110612090058200_CIT0005","first-page":"774","article-title":"Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis","volume":"18","author":"Dunaif","year":"1997","journal-title":"Endocr Rev."},{"issue":"5","key":"2021110612090058200_CIT0006","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1210\/er.2002-0015","article-title":"Insulin-lowering agents in the management of polycystic ovary syndrome","volume":"24","author":"De Leo","year":"2003","journal-title":"Endocr Rev."},{"issue":"2","key":"2021110612090058200_CIT0007","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1210\/endo.142.2.7983","article-title":"Minireview: the glucagon-like peptides","volume":"142","author":"Drucker","year":"2001","journal-title":"Endocrinology."},{"issue":"10077","key":"2021110612090058200_CIT0008","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"le Roux","year":"2017","journal-title":"Lancet."},{"issue":"3","key":"2021110612090058200_CIT0009","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/EJE-13-0797","article-title":"Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin","volume":"170","author":"Jensterle Sever","year":"2014","journal-title":"Eur J Endocrinol."},{"issue":"7","key":"2021110612090058200_CIT0010","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1210\/jc.2008-0115","article-title":"Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome","volume":"93","author":"Elkind-Hirsch","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"2021110612090058200_CIT0011","author":"National Institutes of Health."},{"issue":"3","key":"2021110612090058200_CIT0012","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2021110612090058200_CIT0013","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1055\/a-0664-7583","article-title":"Effect of dapagliflozin on insulin secretion and insulin sensitivity in patients with prediabetes","volume":"128","author":"Ram\u00edrez-Rodr\u00edguez","year":"2020","journal-title":"Exp Clin Endocrinol Diabetes."},{"issue":"4","key":"2021110612090058200_CIT0014","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s13300-018-0449-6","article-title":"A randomized controlled trial of dapagliflozin plus once-weekly exenatide versus placebo in individuals with obesity and without diabetes: metabolic effects and markers associated with bodyweight loss","volume":"9","author":"Pereira","year":"2018","journal-title":"Diabetes Ther."},{"issue":"6","key":"2021110612090058200_CIT0015","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/cen.13968","article-title":"Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study","volume":"90","author":"Javed","year":"2019","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"7056","key":"2021110612090058200_CIT0016","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1136\/bmj.313.7056.559d","article-title":"Ratio of waist circumference to height is strong predictor of intra-abdominal fat","volume":"313","author":"Ashwell","year":"1996","journal-title":"BMJ."},{"key":"2021110612090058200_CIT0017","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.2337\/dc21-S002","article-title":"Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes\u20142021","volume":"44","author":"American Diabetes Association.","year":"2021","journal-title":"Diabetes Care."},{"issue":"3","key":"2021110612090058200_CIT0018","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/j.1550-8528.1999.tb00404.x","article-title":"The use of anthropometric and dual-energy X-ray absorptiometry (DXA) measures to estimate total abdominal and abdominal visceral fat in men and women","volume":"7","author":"Clasey","year":"1999","journal-title":"Obes Res."},{"key":"2021110612090058200_CIT0019","doi-asserted-by":"crossref","first-page":"846578","DOI":"10.1155\/2014\/846578","article-title":"Importance of android\/gynoid fat ratio in predicting metabolic and cardiovascular disease risk in normal weight as well as overweight and obese children","volume":"2014","author":"Samsell","year":"2014","journal-title":"J Obes."},{"issue":"7","key":"2021110612090058200_CIT0020","doi-asserted-by":"crossref","first-page":"e68716","DOI":"10.1371\/journal.pone.0068716","article-title":"Ratio of trunk to leg volume as a new body shape metric for diabetes and mortality","volume":"8","author":"Wilson","year":"2013","journal-title":"PLoS One."},{"issue":"7","key":"2021110612090058200_CIT0021","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia."},{"issue":"9","key":"2021110612090058200_CIT0022","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","article-title":"Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp","volume":"22","author":"Matsuda","year":"1999","journal-title":"Diabetes Care."},{"issue":"10","key":"2021110612090058200_CIT0023","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1464-5491.1995.tb00399.x","article-title":"The 30 minute insulin incremental response in an oral glucose tolerance test as a measure of insulin secretion","volume":"12","author":"Wareham","year":"1995","journal-title":"Diabet Med."},{"issue":"2","key":"2021110612090058200_CIT0024","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/eje.0.1500097","article-title":"Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies","volume":"150","author":"Ahr\u00e9n","year":"2004","journal-title":"Eur J Endocrinol."},{"issue":"6","key":"2021110612090058200_CIT0025","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.2337\/dc06-1331","article-title":"What is the best predictor of future type 2 diabetes?","volume":"30","author":"Abdul-Ghani","year":"2007","journal-title":"Diabetes Care."},{"issue":"1","key":"2021110612090058200_CIT0026","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.1152\/ajpendo.00645.2007","article-title":"Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage","volume":"294","author":"Muniyappa","year":"2008","journal-title":"Am J Physiol Endocrinol Metab."},{"issue":"10","key":"2021110612090058200_CIT0027","doi-asserted-by":"crossref","first-page":"802","DOI":"10.7326\/0003-4819-139-10-200311180-00007","article-title":"Use of metabolic markers to identify overweight individuals who are insulin resistant","volume":"139","author":"McLaughlin","year":"2003","journal-title":"Ann Intern Med."},{"issue":"10","key":"2021110612090058200_CIT0028","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1210\/jcem.84.10.6079","article-title":"A critical evaluation of simple methods for the estimation of free testosterone in serum","volume":"84","author":"Vermeulen","year":"1999","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2021110612090058200_CIT0029","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.metabol.2011.09.009","article-title":"The association between triglyceride to high-density-lipoprotein cholesterol ratio and insulin resistance in a multiethnic primary prevention cohort","volume":"61","author":"Gasevic","year":"2012","journal-title":"Metabolism."},{"issue":"7","key":"2021110612090058200_CIT0030","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1080\/00325481.2017.1342509","article-title":"Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes","volume":"129","author":"Busch","year":"2017","journal-title":"Postgrad Med."},{"issue":"6","key":"2021110612090058200_CIT0031","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/dom.13206","article-title":"Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study","volume":"20","author":"Jabbour","year":"2018","journal-title":"Diabetes Obes Metab."},{"issue":"12","key":"2021110612090058200_CIT0032","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","article-title":"Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial","volume":"4","author":"Fr\u00edas","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"2021110612090058200_CIT0033","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr."},{"issue":"4","key":"2021110612090058200_CIT0034","doi-asserted-by":"crossref","first-page":"912","DOI":"10.2337\/dc13-1518","article-title":"Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release","volume":"37","author":"Garvey","year":"2014","journal-title":"Diabetes Care."},{"key":"2021110612090058200_CIT0035","doi-asserted-by":"crossref","first-page":"d7771","DOI":"10.1136\/bmj.d7771","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials","volume":"344","author":"Vilsb\u00f8ll","year":"2012","journal-title":"BMJ."},{"issue":"7","key":"2021110612090058200_CIT0036","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1471-0528.2006.00966.x","article-title":"The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome\u2014a randomised, double-blind, placebo-controlled trial","volume":"113","author":"Lord","year":"2006","journal-title":"BJOG."},{"issue":"11","key":"2021110612090058200_CIT0037","first-page":"3227","article-title":"Portal insulin concentrations rather than insulin sensitivity regulate serum sex hormone-binding globulin and insulin-like growth factor binding protein 1 in vivo","volume":"80","author":"Yki-J\u00e4rvinen","year":"1995","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"2021110612090058200_CIT0038","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.tem.2015.05.001","article-title":"Novel insights in SHBG regulation and clinical implications","volume":"26","author":"Sim\u00f3","year":"2015","journal-title":"Trends Endocrinol Metab."},{"issue":"6","key":"2021110612090058200_CIT0039","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/0022-4731(83)90260-1","article-title":"Dynamics of SHBG response to testosterone. Implications upon the immediate biological effect of sex hormones","volume":"18","author":"Belgorosky","year":"1983","journal-title":"J Steroid Biochem."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab408\/38973625\/dgab408.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/10\/3019\/41098088\/dgab408.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/10\/3019\/41098088\/dgab408.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T08:10:21Z","timestamp":1636186221000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/106\/10\/3019\/6294193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,6,7]]},"published-print":{"date-parts":[[2021,9,27]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab408","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,6,7]]}}}